China-focused investment firms CDH Investments and Leadyond Capital, have led a RMB 250 million ($38.9 million) Series B round into Chengdu (China)-based HitGen Ltd, a drug discovery research firm, according to a company statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
